Aerosolized Ceftazidime for Prevention of Ventilator-Associated Pneumonia and Drug Effects on the Proinflammatory Response in Critically Ill Trauma Patients

G. Christopher Wood, Pharm.D., Bradley A. Boucher, Pharm.D., FCCP, Martin A. Croce, M.D., Scott D. Hanes, Pharm.D., Vanessa L. Herring, B.S., Timothy C. Fabian, M.D.

Disclosures

Pharmacotherapy. 2002;22(8) 

In This Article

Conclusion

The results of this preliminary study show that a short course of aerosolized ceftazidime significantly decreases the frequency of VAP in critically ill trauma patients, without adversely affecting bacterial pathogen and sensitivity patterns. The data also suggest that aerosolized ceftazidime may attenuate selected proinflammatory cytokines in the lung, and that this attenuation is related to decreased development of VAP. Nonetheless, additional trials of prophylactic aerosolized antibiotics are needed before this pharmacotherapeutic modality can be advocated for widespread administration. Outstanding issues to be resolved include refinement of patient selection; optimal drug regimens; effects on morbidity, mortality, and ICU flora; and the role of immunomodulation. Regardless, the results of this study show that limited aerosolized antibiotic therapy may be effective for preventing VAP in critically ill trauma patients.

Presented in part at the annual meeting of the American College of Clinical Pharmacy, Los Angeles, California, November 5-8, 2000.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....